Clinical trials: Large B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Zevalin-beam for Aggressive Lymphoma
The study hypothesis is that the addition of zevalin radioimmunotherapy to the conditioning regimen given prior to BEAM high-dose chemotherapy and autologous stem cell transplantation in patients with aggressive lymphoma will…
- Trial name
- NCT00491491
- Testing
- ibritumomab tiuxetan, BEAM chemotherapy and autologous stem-cell transplantation
- Where
- 9 sites in United States, Germany and 2 more
- Volunteers
- 60 people
- Sponsor
- Sheba Medical Center
Diffuse Large Cell Lymphoma, Non-Hodgkin Lymphoma
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
Background: Non-Hodgkin lymphoma (NHL) is the most common cancer among people living with HIV in the United States. People with HIV are up to 17 times more likely to get NHL than people who do not have HIV.
- Conditions
- Diffuse Large Cell Lymphoma, Non-Hodgkin Lymphoma, Burkitt Lymphoma, Plasmablastic Lymphoma
- Trial name
- NCT05389423
- Testing
- Vincristine, Prednisone, Doxorubicin
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Diffuse Large B-Cell Lymphoma
An Observational Study of MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in First-Line in Patients With Diffuse Large B-Cell Lymphoma
This multicenter, observational study will evaluate the correlation between clinical and biological factors and International Prognostic Index (IPI) as prognostic factors in patients with diffuse large B-cell lymphoma receiving…
- Trial name
- NCT01724294
- Where
- Romania
- Volunteers
- 113 people
- Sponsor
- Hoffmann-La Roche
Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia
Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer
This clinical trial studies massage therapy given by caregiver in treating quality of life of young patients undergoing treatment for cancer.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Angioimmunoblastic T-cell Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
- Trial name
- NCT01053494
- Testing
- massage therapy, questionnaire administration, quality-of-life assessment
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Wake Forest University Health Sciences
Fever, Sweats, and Hot Flashes, Infection
Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia
RATIONALE: Levofloxacin may be effective in reducing fever and controlling other symptoms of neutropenia in patients who are being treated for cancer.
- Conditions
- Fever, Sweats, and Hot Flashes, Infection, Leukemia, Lymphoma
- Trial name
- NCT00020865
- Testing
- cefepime hydrochloride, levofloxacin
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Mantle Cell Lymphoma, Diffuse Large B-cell Lymphoma
A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
This study is designed to explore the safety and tolerability of RD14-01 for patients with relapsed and/or refractory B-cell non-Hodgkin lymphoma. And to evaluate the efficacy and pharmacokinetics of RD14-01 in patients.
- Conditions
- Mantle Cell Lymphoma, Diffuse Large B-cell Lymphoma, Follicular Lymphoma
- Trial name
- NCT05444322
- Testing
- RD14-01 cell infusion
- Where
- China
- Volunteers
- 18 people
- Sponsor
- He Huang
Lymphoma, Large B-Cell, Diffuse
Identification Predictive Markers of Immunochemotherapy Response to the Primary Cutaneous Diffuse Large B Cell Lymphoma
The study is performed on a single-center retrospective cohort of 32 patients LBC-TJ treated with R-chemotherapy for which data collection was carried out in homogeneous and prospectively followed according to international…
- Trial name
- PROTEOM (NCT04183569)
- Testing
- Sequencing RNA.
- Where
- France
- Volunteers
- 32 people
- Sponsor
- University Hospital, Bordeaux
Large B-cell Lymphoma
NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma
Diffuse large B-cell lymphoma is the most commonly occurring subtype of non-Hodgkin lymphoma, but treatment is often not curative, with as many as 50% of patients with adverse risk factors developing relapsed/refractory disease.
- Trial name
- NCT07052305
- Testing
- NT-I7, CAR T-cell therapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Washington University School of Medicine
Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
This phase Ib/II trial studies the side effects and efficacy of maintenance acalabrutinib following cellular therapy in treating patients with large B-cell lymphoma at very high risk of the cancer coming back.
- Conditions
- Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma, Transformed Lymphoma, Secondary Central Nervous System Lymphoma
- Trial name
- NCT05256641
- Testing
- Acalabrutinib
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma
Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction
Phase I trial to study the effectiveness of bortezomib in treating patients who have advanced cancer and kidney dysfunction. Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma
- Trial name
- NCT00054483
- Testing
- bortezomib, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- National Cancer Institute (NCI)
Large B-cell Lymphoma, TP53
The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study
This is a Phase II, open-label, single-arm, multicenter study designed to evaluate the safety and efficacy of a novel combination therapy-Glofitamab, a PD-1 inhibitor, and Lenalidomide (Glofit-PD-1-Len)-in patients with…
- Trial name
- NCT07240194
- Testing
- Glofitamab, PD-1 Inhibitor, Lenalidomide
- Where
- China
- Volunteers
- 24 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Breast Cancer, Chronic Myeloproliferative Disorders
Study of the Emotional Needs of Caregivers of Stem Cell Transplantation Patients
RATIONALE: Understanding the emotional needs of spouses or others who are living with and caring for patients who have undergone stem cell transplantation may help improve the quality of life of both the caregivers and the…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia
- Trial name
- NCT00082654
- Testing
- psychosocial assessment and care
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Hematologic Malignancy, Leukemia
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting.
- Conditions
- Hematologic Malignancy, Leukemia, Lymphoma, Acute Lymphocytic Leukemia
- Trial name
- NCT06131801
- Testing
- 1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care.
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Lymphoma, Large B-Cell, Diffuse
RCHOP Chemoimmunotherapy Preceded BY BBB Permeabilization by t-NGR Necrosis Factor
Patients with primary central nervous system lymphoma (PCNSL) are treated with high-dose-methotrexate-based chemotherapy, which requires hospitalization and extensive expertise to manage related toxicity.
- Trial name
- INGRID (NCT03536039)
- Testing
- NGR-hTNF, RITUXIMAB, Doxorubicin
- Where
- Italy
- Volunteers
- 28 people
- Sponsor
- Andres J. M. Ferreri
Non-Hodgkin's Lymphoma
Allo-hNHL (FluBuCy)
DSHNHL R3 is a randomized clinical phase II study. The main objective is to estimate the efficacy of rituximab as a prophylactic medication for prevention of graft-versus-host-disease after allogeneic peripheral stem cell…
- Trial name
- NCT00785330
- Testing
- standard GVHD prophylaxis, rituximab
- Where
- 6 sites in Germany
- Volunteers
- 84 people
- Sponsor
- Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
Primary Central Nervous System Lymphoma, Diffuse Large B-Cell Lymphoma
R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lymphoma
This is a prospective, open-label, multicenter, randomized controlled study in treatment-naive patients with primary central nervous system lymphoma (PCNSL, DLBCL type).
- Trial name
- RM-MA-PD1 (NCT07764601)
- Testing
- Penpulimab, Rituximab, Methotrexate
- Where
- 5 sites in China
- Volunteers
- 58 people
- Sponsor
- WEI XU
Diffuse Large B Cell Lymphoma, Patient Reported Outcome
The Potential of Patient-reported Outcome Measures in Detection of Relapse in Diffuse Large B-cell Lymphoma
Annually some 450 patients are diagnosed with Diffuse Large B-cell Lymphoma (DLBCL), in Denmark. The majority of these patients are cured with immunochemotherapy, but up to 30 % will relapse, pointing to the need for targeted…
- Trial name
- NCT04695366
- Testing
- No intervention
- Where
- Denmark
- Volunteers
- 250 people
- Sponsor
- Herlev Hospital
Lymphoma, Diffuse Large B-Cell
PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)
This study is sponsored by Sierra Oncology, Inc. formerly ProNAi Therapeutics, Inc. It is a multi-center, nonrandomized, open label, phase II investigation of PNT2258 to characterize anti-tumor activity and collect safety data on…
- Trial name
- NCT02226965
- Testing
- PNT2258
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 45 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Lymphoma, Small Intestine Cancer
VNP40101M in Treating Patients With Advanced or Metastatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of VNP40101M in treating patients who have advanced or…
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00049699
- Testing
- laromustine
- Where
- 3 sites in United States
- Sponsor
- Vion Pharmaceuticals
Lymphoma, Large B-Cell, Diffuse
Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma
This Phase I clinical trial studies the side effects and maximum tolerated dose (MTD) of the combination of brentuximab vedotin (BV) and lenalidomide in the treatment of patients with relapsed or refractory diffuse large B-cell…
- Trial name
- NCT02086604
- Testing
- Brentuximab vedotin, Lenalidomide
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Washington University School of Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.